Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Likeability and abuse liability of commonly prescribed opioids.

Wightman R, Perrone J, Portelli I, Nelson L.

J Med Toxicol. 2012 Dec;8(4):335-40. doi: 10.1007/s13181-012-0263-x. Review.

2.

Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL.

Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4.

3.

The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.

Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr.

Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007.

4.

Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.

Zacny JP, Lichtor SA.

Psychopharmacology (Berl). 2008 Jan;196(1):105-16. Erratum in: Psychopharmacology (Berl). 2008 Jan;196(1):117.

5.

Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

Cicero TJ, Inciardi JA, Muñoz A.

J Pain. 2005 Oct;6(10):662-72.

PMID:
16202959
6.

Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.

Zacny JP, Gutierrez S.

Drug Alcohol Depend. 2009 Apr 1;101(1-2):107-14. doi: 10.1016/j.drugalcdep.2008.11.013.

PMID:
19118954
7.

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.

Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE.

Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3.

8.

Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products.

Zacny JP, Gutierrez S.

Pain Med. 2008 May-Jun;9(4):433-43. doi: 10.1111/j.1526-4637.2007.00359.x.

PMID:
18489634
9.

Abuse liability assessment of hydrocodone under current draft regulatory guidelines.

Gauvin DV, McComb M, Code R, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:118-29. doi: 10.1016/j.vascn.2015.05.003.

PMID:
25969422
10.

Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011.

Atluri S, Sudarshan G, Manchikanti L.

Pain Physician. 2014 Mar-Apr;17(2):E119-28.

11.

Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.

Cicero TJ, Surratt H, Inciardi JA, Munoz A.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):827-40.

PMID:
17636553
12.

Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Compton WM, Volkow ND.

Drug Alcohol Depend. 2006 Feb 1;81(2):103-7. Review.

PMID:
16023304
13.
14.
15.

Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.

Zacny JP, Gutierrez S.

Psychopharmacology (Berl). 2011 Dec;218(3):471-81. doi: 10.1007/s00213-011-2349-6.

PMID:
21603891
16.

Oxycodone for cancer-related pain.

Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS.

Cochrane Database Syst Rev. 2015 Feb 27;(2):CD003870. doi: 10.1002/14651858.CD003870.pub5. Review.

PMID:
25723351
17.

Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.

Wiffen PJ, Derry S, Moore RA.

Cochrane Database Syst Rev. 2014 May 29;(5):CD011056. doi: 10.1002/14651858.CD011056.pub2. Review.

PMID:
24874470
18.

Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.

White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J.

J Opioid Manag. 2015 May-Jun;11(3):199-210. doi: 10.5055/jom.2015.0269.

PMID:
25985805
19.

Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.

Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF.

Pain Med. 2014 Mar;15(3):440-51. doi: 10.1111/pme.12295.

PMID:
24330279
20.

Assessment of the abuse of tapentadol immediate release: the first 24 months.

Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH.

J Opioid Manag. 2012 Nov-Dec;8(6):395-402. doi: 10.5055/jom.2012.0139.

PMID:
23264317
Items per page

Supplemental Content

Support Center